Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting
SEATTLE, WA., July 27, 2017 – Adaptive Biotechnologies, the pioneer in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces the appointment of Mr. Gene DeFelice to SVP and General Counsel, and Dr. Alexandra Snyder to Translational Medicine Lead for Adaptive Research. Both Mr. DeFelice and Dr. Snyder bring significant experience that will provide strategic and scientific guidance to the existing and future products and services that Adaptive provides.
Mr. DeFelice has over 30 years of legal experience and over 20 years in healthcare, including diagnostics, biotechnology, pharmaceuticals, and medical devices. Having served as General Counsel for several public healthcare and technology companies, including a role as primary counsel at Roche Diagnostics, Mr. DeFelice will join the Executive Team to implement a legal infrastructure that prepares Adaptive for strategic decision-making to lead in the rapidly expanding market for clinical applications of NGS technologies.
“Gene has an extensive background across healthcare and other industries in legal and strategic operations that will raise Adaptive’s capabilities to the next level,” said Chad Robins, President, Chief Executive Officer and Co-Founder of Adaptive. “As we near our first FDA submission and evaluate critical partnering opportunities for Adaptive Therapeutics, the depth of Gene’s expertise will be immediately applicable to these key inflection points for the company.”
Complementing the strength of Mr. DeFelice’s background, Dr. Alex Snyder is joining Adaptive from Memorial Sloan Kettering Cancer Research Center as one of the premiere emerging physician scientists specializing in the study of tumor immunogenomics and response-to-checkpoint blockade immunotherapy. Dr. Snyder has been a long-time collaborator of Adaptive’s after evaluating the benefits of T-cell receptor sequencing in relation to mutational burden in the development of immunotherapy biomarkers.
“Alex has been a pleasure to work with over the years and it comes as no surprise that the feedback we have received at Adaptive upon her arrival has been fantastic,” said Dr. Harlan Robins, Head of Innovation and Co-Founder at Adaptive. “Alex’s commitment to translating immune profiling data into clinical practice is aligned with Adaptive’s goal of developing a measure of a patient’s immune agility to guide clinical decision-making.”
About Adaptive Biotechnologies
Adaptive Biotechnologies is a pioneer in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information, please visit www.adaptivebiotech.com.